Drugs by condition
Drugs approved for overactive bladder
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
7
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
5
New molecular entities and new biologics
In development
1
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for overactive bladder.
- Myrbetriq Granules (Mirabegron) · Apgdi Priority reviewMar 25, 2021
- Gemtesa (Vibegron) · Sumitomo Pharma Am NovelDec 23, 2020
- Myrbetriq (Mirabegron) · Apgdi NovelJun 28, 2012
- Toviaz (Fesoterodine Fumarate) · Pfizer NovelOct 31, 2008
- Oxytrol (Oxybutynin) · Allergan Feb 26, 2003
All approved drugs for overactive bladder, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 60 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
beta3-Adrenergic Agonist (3)
- Gemtesa Vibegron · Sumitomo Pharma Am · 2020
- Myrbetriq Mirabegron · Apgdi · 2012
- Myrbetriq Granules Mirabegron · Apgdi · 2021
Acetylcholine Release Inhibitor (1)
- Botox Cosmetic Onabotulinumtoxina · Allergan · 1991
Cholinergic Muscarinic Antagonist (1)
- Oxytrol Oxybutynin · Allergan · 2003
Class not listed in FDA's data (2)
Drugs in development for overactive bladder
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- TRG-200Phase 21 trial
Trigone Pharma Ltd. · Overactive Bladder (OAB)
More on overactive bladder: recruiting trials · published research
Related in kidney and urology: Chronic kidney disease · IgA nephropathy · Enlarged prostate (BPH) · Erectile dysfunction
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.